Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Omics-Based Clinical Trials Sector?
In recent times, the market size for omics-based clinical trials has witnessed robust growth. The market, which is projected to rise from $29.10 billion in 2024 to $31.71 billion in 2025, will experience a compound annual growth rate (CAGR) of 8.9%. Factors contributing to previous growth include the surge in clinical trials utilizing omics technologies, increased focus on translational research, escalating governmental backing and funds, improved access to biobanks and biospecimens, and rising knowledge about the advantages of precision therapies.
The market for clinical trials based on omics is predicted to see significant expansion in the coming years. With a compound annual growth rate (CAGR) estimated at 8.6%, it is expected to reach $44.08 billion by 2029. Several factors are contributing to this growth forecast, such as the rising demand for customized medical treatments, the increasing usage of multi-omics methods, a growing incidence of both chronic and rare diseases, heightened investment in genomic research and biotechnology, and a greater focus on discovering new biomarkers. During the forecast period, the notable trends include advances in Next-Generation Sequencing (NGS) technologies, the incorporation of artificial intelligence into omics platforms, technological progress in bioinformatics tools, enhancements in proteomics and metabolomics platforms, and the amalgamation of multi-omics data.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp
What Forces Are Driving The Growth Of The Omics-Based Clinical Trials Market?
The growth of the omics-based clinical trials market is anticipated to be propelled by an escalating demand for personalized medicine. Personalized medicine is a medical strategy that customizes the prevention, diagnosis, and treatment of diseases according to the unique characteristics of each patient. With advancements in genomic technologies enabling quicker, cost-effective analysis of individual genetic profiles, there has been a surge in demand for personalized medicine. Omics-based clinical trials provide crucial support in this domain, helping identify unique genetic, proteomic, and metabolic profiles of individuals. This facilitates the development of more precise and effective treatment methodologies personalized for each patient. For example, as noted by the Personalized Medicine Coalition, a professional association in the US, in 2022, of the 12 new custom-made medicines approved, 34% signified all newly approved treatments, marking a significant increase from past years. Therefore, the surge in demand for personalized medicine is fuelling the omics-based clinical trials market’s expansion.
How Is The Omics-Based Clinical Trials Industry Segmented Across Key Parameters?
The omics-based clinical trials market covered in this report is segmented
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling
What Notable Trends Are Shaping The Direction Of The Omics-Based Clinical Trials Market?
Leading firms in the omics-based clinical trials market are emphasizing on innovative solutions, such as HiFi sequencing technology, to improve the precision, velocity, and complexity of multi-omics data examination, with the goal of enhancing trial results and bespoke treatment plans. HiFi sequencing is a next-generation sequencing (NGS) technology that provides long, highly precise reads via circular consensus sequencing (CCS), facilitating thorough and exact analysis of genomes, transcriptomes, and epigenomes. For example, in October 2024, Pacific Biosciences of California Inc., a biotech company from the US, in partnership with the Agency for Science, Technology, and Research (A*STAR), a research and product development agency from Singapore, and Macrogen Inc., a biotech company from South Korea, inaugurated an advanced lab to push forward genomics innovation in Singapore using the superior long-read sequencing technology. The establishment gives researchers the opportunity to execute in-depth genomic studies with greater accuracy and rapidity. It caters to a plethora of applications, including transcriptomics, whole genome sequencing, metagenomics, and epigenetics. The lab also encourages cooperation among global scientists and local institutions, with the objective to expedite breakthroughs in precision oncology, personalized medicine, and rare disease diagnosis. Furthermore, it provides training schemes and shared access to high-throughput sequencing facilities, fostering innovation and capacity-building within the Asia-Pacific region.
Which Companies Currently Dominate The Competitive Landscape In The Omics-Based Clinical Trials Industry?
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report
Which Geographic Regions Are Driving Demand In The Omics-Based Clinical Trials Market?
North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model